NALP8 Inhibitors
Chemical inhibitors of NALP8 can exert their inhibitory effects through various cellular and molecular pathways that indirectly impact the functional activity of this protein. MCC950, for example, is known to block the NLRP3 inflammasome, a component of the NLRP family to which NALP8 belongs. The inhibition of NLRP3 can lead to a reduction in NALP8 activity due to shared pathways and regulatory mechanisms. Similarly, Glyburide targets the NLRP3 inflammasome and prevents its activation, which can result in decreased activation of NALP8, given their structural and functional similarities within the NLRP family. Bay 11-7082 and Parthenolide focus on the NF-κB pathway, crucial for the expression and activation of several NLRP proteins, including NALP8. By inhibiting NF-κB, these chemicals reduce the transcriptional activation of inflammatory proteins that contribute to NALP8 activity.
In addition, Infliximab and Anakinra act on cytokine signaling; Infliximab by inhibiting TNF-α, and Anakinra by antagonizing the interleukin-1 receptor, both lead to reduced signaling that can activate NALP8. Ruxolitinib targets the JAK-STAT pathway, involved in cytokine regulation, which can decrease the signaling cascade leading to NALP8 activation. Belnacasan specifically targets caspase-1, an enzyme crucial to inflammasome activation, thus reducing NALP8-associated inflammasome activity. Oridonin can inhibit multiple signaling pathways, including NF-κB, which impacts the regulation of NLRP proteins, thereby decreasing NALP8 activity. Oridonin can also covalently modify cysteine residues, which may disrupt the function of NLRP inflammasomes and impact NALP8 indirectly. Lastly, Tranilast modulates the release of inflammatory mediators that can influence the activation of NLRP8 by affecting related signaling pathways and the release of activators.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MCC950 sodium salt | 256373-96-3 | sc-505904 sc-505904A sc-505904B sc-505904C | 5 mg 10 mg 50 mg 100 mg | $114.00 $198.00 $888.00 $1569.00 | 3 | |
MCC950 directly inhibits NALP8 by blocking the NLRP3 inflammasome, which is a component of the same family of pattern recognition receptors to which NALP8 belongs. Inhibition of NLRP3 can lead to a reduction in the activity of NALP8 due to the shared pathways and regulatory mechanisms within the NLRP family. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
Parthenolide inhibits NALP8 through its action on the NF-κB pathway, which is crucial for the expression and activation of several NLRP proteins. By inhibiting NF-κB, Parthenolide reduces the activity of NALP8, as NF-κB is necessary for the transcriptional activation of many inflammatory proteins, including those in the NLRP family. | ||||||
Glyburide (Glibenclamide) | 10238-21-8 | sc-200982 sc-200982A sc-200982D sc-200982B sc-200982C | 1 g 5 g 25 g 100 g 500 g | $46.00 $61.00 $117.00 $173.00 $530.00 | 36 | |
Glyburide inhibits NALP8 indirectly by targeting the NLRP3 inflammasome and preventing its activation. Given the structural and functional similarities within the NLRP family, the inhibition of NLRP3 can lead to decreased activation of NALP8. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Bay 11-7082 inhibits NALP8 by targeting the NF-κB pathway, which is implicated in the regulation of NLRP proteins. By inhibiting IκBα phosphorylation, it prevents NF-κB from translocating to the nucleus and activating inflammatory genes that can contribute to NALP8 activity. | ||||||
Anakinra | 143090-92-0 | sc-507486 | 10 mg | $811.00 | ||
Anakinra, an interleukin-1 receptor antagonist, indirectly inhibits NALP8 by blocking IL-1β signaling. Given that IL-1β is a downstream product of inflammasome activity, blocking its receptor can reduce the functional activity of NLRP proteins, including NALP8. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib inhibits NALP8 indirectly by targeting the JAK-STAT pathway, which is involved in the signaling of cytokines that regulate NLRP protein functions. By inhibiting this pathway, ruxolitinib can reduce the signaling cascade that leads to NALP8 activation. | ||||||
VX-765 | 273404-37-8 | sc-475845 sc-475845A sc-475845B | 5 mg 10 mg 50 mg | $228.00 $302.00 $968.00 | 1 | |
Belnacasan inhibits NALP8 indirectly by specifically targeting the caspase-1 which is a key enzyme in the activation of the inflammasome complex, to which NALP8 contributes. Inhibition of caspase-1 leads to a decrease in NALP8 associated inflammasome activity. | ||||||
Oridonin, R. rubescens | 28957-04-2 | sc-202751 | 5 mg | $77.00 | ||
Oridonin inhibits NALP8 by targeting multiple signaling pathways, including NF-κB, which impacts the regulation and activity of NLRP proteins. Inhibition of these pathways can decrease the functional activity of NALP8. | ||||||
Tranilast | 53902-12-8 | sc-200389 sc-200389A sc-200389B sc-200389C | 10 mg 50 mg 1 g 5 g | $31.00 $103.00 $283.00 $978.00 | 2 | |
Tranilast indirectly inhibits NALP8 by modulating the release of inflammatory mediators and affecting signaling pathways, such as the release of NLRP3 activators, which can influence the NALP8 inflammasome activity. | ||||||